GetTopicDetailResponse(id=61a01045234e, topicName=多格列艾汀, introduction=多格列艾汀, content=多格列艾汀糖尿病, image=null, comments=2, allHits=1281, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=10, adminEncryptionId=7a3710, adminName=賽華佗, createdBy=7a3710, createdName=賽華佗, createdAvatar=, createdTime=Sat May 14 18:57:53 CST 2022, time=2022-05-14, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=437940, tagList=[TagDto(tagId=437940, tagName=多格列艾汀)], ipAttribution=, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2093004, encodeId=f8f3209300429, content=<a href='/topic/show?id=61a01045234e' target=_blank style='color:#2F92EE;'>#多格列艾汀#</a>, objectTitle=全球首創(chuàng)降糖新藥華堂寧?獲批， 拜耳建立糖尿病全病程管理模式, objectType=article, longId=742772, objectId=055fe4277258, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/400x240.jpg, objectUrl=/article/show_article.do?id=055fe4277258, replyNumber=0, likeNumber=130, createdTime=2022-10-11, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=055fe4277258, moduleTitle=全球首創(chuàng)降糖新藥華堂寧?獲批， 拜耳建立糖尿病全病程管理模式, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=055fe4277258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1219625, encodeId=50e9121962540, content=<a href='/topic/show?id=61a01045234e' target=_blank style='color:#2F92EE;'>#多格列艾汀#</a><a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, objectTitle=Nat Med：兩項多格列艾汀的III期研究結果公布，降糖作用顯著且長期持續(xù), objectType=article, longId=726861, objectId=e4bce268618c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220512/d1ec25813bc348c8885e84944dbfdedd.jpg, objectUrl=/article/show_article.do?id=e4bce268618c, replyNumber=0, likeNumber=213, createdTime=2022-05-14, rootId=0, userName=賽華佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4bce268618c, moduleTitle=Nat Med：兩項多格列艾汀的III期研究結果公布，降糖作用顯著且長期持續(xù), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e4bce268618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
賽華佗
2022-05-14
